Japan's Oncolys begins PhI trial of cancer drug licensed from Astellas

Japan's Oncolys BioPharma has started a U.S.-based Phase I trial of cancer drug candidate OBP-801 licensed from Astellas Pharma in 2009. The company listed on the Tokyo Stock Exchange Mothers Market in 2013 and said in a press release last week that the first patients received the drug in May in a trial to evaluate intravenous safety and efficacy on solid cancers. After preclinical work, Oncolys submitted an IND application to the U.S. FDA in November of 2014. Release (Japanese)